Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2007.0069PMID 17927925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single agent versus combination chemotherapy for metastatic breast cancer.

  2009cited by this paper
• Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva.

  2004cited by this paper
• Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

  2003cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cited by this paper
• Construction and validation of a practical prognostic index for patients with metastatic breast cancer.

  1998cited by this paper
• Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.

  1976cited by this paper

• Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.

  2013cites this paper
• Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice

  2013cites this paper
• Predicting the Toxicity of Adjuvant Breast Cancer Drug Combination Therapy

  2012cites this paper
• Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

  2011cites this paper
• Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.

  2010cites this paper
• Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

  2009cites this paper
• Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

  2008cites this paper